Received Sep 10, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HEP | HEP B (HEPLISAV-B) | DYNAVAX TECHNOLOGIES CORPORATION | 2 | — | — |
Received HEPLISAV-B then Received Another Hepatitis B Shot; Initial report received on 25-Aug-2025. A consumer reported that she, a female patient, received HEPLISAV-B (hepatitis B vaccine) for the first dose of hepatitis B immunization, then received an unknown hepatitis B vaccine , and then received the second dose of HEPLISAV-B. No medical history or concomitant medications were reported. In Jul-2025, the patient received dose 1 of a hepatitis B vaccine [HEPLISAV-B (lot number, expiration date, NDC number, route, and site not available)]. On 18-Aug-2025, approximately one month after receiving HEPLISAV-B, the patient received an unknown hepatitis B vaccine (lot number, expiration date, route, and site not available). On 22-Aug-2025, approximately one month after receiving HEPLISAV-B and 4 days after receiving a dose of an unknown hepatitis B vaccine , the patient received dose 2 of HEPLISAV-B (lot number, expiration date, NDC number, route, and site not available). The reporter declined to provide further information. Company Comment: The company assessed the event as non-serious.; Sender's Comments: The company assessed the event as non-serious.
Hepatitis b vaccine